A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects
Arnaldo J Acosta G, Eesha Chitneni, Claudia Jeanette Manzanares Vidals, Sravani Modumudi, Sobia Hammad, Ashee Verma, Rahul Y Rajesh, Aimen Khaliq, Olaoluwa Adeyemi, Farhat Majeed, Rucha V Gujar
TL;DR
New diabetes drugs like SGLT2 inhibitors and GLP-1 RA improve heart health and reduce risks like heart failure and stroke.
Contribution
A literature review highlighting cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 RA in diabetics and non-diabetics.
Findings
SGLT2 inhibitors reduce heart failure hospitalizations and slow chronic kidney disease progression.
GLP-1 RA lower stroke risk and improve cardiovascular outcomes.
Both drug classes offer significant cardiovascular benefits beyond glucose control.
Abstract
The discovery of inhibitors for sodium-glucose cotransporter 2 (SGLT2) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) has significantly improved type 2 diabetes management. Large-scale clinical studies have shown that both SGLT2 inhibitors and GLP-1 RA enhance cardiovascular health. Benefits include reduced cardiovascular disease risk, lower mortality, fewer heart failure hospitalizations (SGLT2 inhibitors), and stroke prevention (GLP-1 RA). Additionally, these drugs slow chronic kidney disease progression. This comprehensive treatment targets vascular events. Despite differences, both drug classes are crucial. GLP-1 RA mainly reduce stroke risk, while SGLT2 inhibitors alleviate heart failure. Our findings, based on a literature review, will address the renal and cardiac effects of SGLT2 inhibitors and GLP-1 RA in both diabetics and non-diabetics, highlighting their combined…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetes Treatment and Management · Pancreatic function and diabetes · Diabetes Management and Research